Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 2/20 | 0.34 |
| ▸ | NOS2 | P35228 | 2/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7127321 | 0.80 | KDM4E (0.46) | KDM4EALDH1A1HPGDUSP2HSD17B10 | |
| SCHEMBL5630218 | 0.79 | NOS3 (0.33) | NOS3NOS2NOS1 | |
| SCHEMBL9550990 | 0.77 | KDM4E (0.32) | KDM4EALDH1A1KMT2AOPRK1NOS3 | |
| SCHEMBL9007842 | 0.77 | KDM4E (0.67) | KDM4EALDH1A1HPGDUSP2HSD17B10 | |
| SCHEMBL29672807 | 0.76 | KDM4E (0.65) | KDM4EALDH1A1HPGDUSP2HSD17B10 | |
| SCHEMBL17433348 | 0.76 | KDM4E (0.43) | KDM4EALDH1A1HPGDUSP2HSD17B10 | |
| SCHEMBL18806278 | 0.76 | KDM4E (0.43) | KDM4EALDH1A1HPGDUSP2HSD17B10 | |
| SCHEMBL22853883 | 0.76 | KDM4E (0.65) | KDM4EALDH1A1HPGDUSP2HSD17B10 | |
| Hydrochloric Acid SCHEMBL18764595 | 0.76 | KDM4E (0.39) | KDM4EALDH1A1HPGDUSP2HSD17B10 | |
| SCHEMBL10392770 | 0.74 | KDM4E (0.42) | KDM4EALDH1A1HPGDUSP2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2865446-B1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SECONDARY ALCOHOL | KANTO KAGAKU (JP) | 2021-09-22 | — | — | EP | claimed |
| US-9174906-B2 | Process for producing optically active secondary alcohol | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2015-11-03 | — | — | US | claimed |
| EP-2865446-A1 | Process for producing optically active secondary alcohol | Kanto Kagaku Kabushiki Kaisha (JP) | 2015-04-29 | — | — | EP | claimed |
| US-20150031920-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SECONDARY ALCOHOL | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2015-01-29 | — | — | US | claimed |
| EP-2865446-B1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SECONDARY ALCOHOL | KANTO KAGAKU (JP) | 2021-09-22 | — | — | EP | disclosed |
| US-10472347-B2 | Aminopyrazine compounds with A2A antagonist properties | MERCK SHARP & DOHME CORP. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10472347-B2 | Aminopyrazine compounds with A2A antagonist properties | MERCK SHARP & DOHME CORP. (US) | 2019-11-12 | — | — | US | disclosed |
| US-20180327385-A1 | AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2018-11-15 | — | — | US | disclosed |
| EP-3220910-A1 | AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | Merck Sharp & Dohme Corp. (US) | 2017-09-27 | — | — | EP | disclosed |
| WO-2016081290-A1 | AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016081290-A1 | AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2016-05-26 | — | — | WO | disclosed |
| US-9174906-B2 | Process for producing optically active secondary alcohol | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2015-11-03 | — | — | US | disclosed |
| EP-2865446-A1 | Process for producing optically active secondary alcohol | Kanto Kagaku Kabushiki Kaisha (JP) | 2015-04-29 | — | — | EP | disclosed |
| US-20150031920-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SECONDARY ALCOHOL | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2015-01-29 | — | — | US | disclosed |
| US-7875600-B2 | Pyrimidine compounds as purine receptor antagonist | VERNALIS (R&D) LIMITED (GB) | 2011-01-25 | — | — | US | disclosed |
| US-20070281936-A1 | To reducte the purinergic neurotransmission; Parkinson's disease; dyskinesias; Movement disorders; Adenosine receptors antagonists; 2-Methylamino-6-(5-methyl-2-furyl)-N-(2-pyridylmethyl)pyrimidine-4-carboxamide | VERNALIS (R & D ) LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| EP-1720553-A1 | PYRIMIDINE COMPOUNDS AS PURINE RECEPTOR ANTAGONIST | VERNALIS (R&D) LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005079801-A1 | PYRIMIDINE COMPOUNDS AS PURINE RECEPTOR ANTAGONIST | VERNALIS (R & D) LTD (GB) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031920-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SECONDARY ALCOHOL | ADH1A, ADH1C, ADH5 | KDM4E 1802/4885ALDH1A1 9/4885HPGD 887/4885 |
| US-20070281936-A1 | To reducte the purinergic neurotransmission; Parkinson's disease; dyskinesias; Movement disorders; Adenosine receptors antagonists; 2-Methylamino-6-(5-methyl-2-furyl)-N-(2-pyridylmethyl)pyrimidine-4-carboxamide | ADORA2A, ADORA3, ADORA1 | KDM4E 3444/4885ALDH1A1 562/4885HPGD 982/4885 |
| US-10472347-B2 | Aminopyrazine compounds with A2A antagonist properties | ADORA2A, ADORA1, ADORA3 | KDM4E 3600/4885ALDH1A1 591/4885HPGD 1913/4885 |
| US-20180327385-A1 | AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | ADORA2A, ADORA1, ADORA3 | KDM4E 3600/4885ALDH1A1 591/4885HPGD 1913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.